Roberto Wandenkolk Vieira, President of Oncology at Corcept Therapeutics Inc (NASDAQ:CORT), filed a Form 4 on November 4, 2026, disclosing transactions in common stock and a stock option on November 2, 2026.

Key Highlights

  • Option exercise: Vieira exercised a stock option covering 8,333 shares of common stock at an exercise price of $21.63 per share on November 2, 2026.
  • First sale tranche: 6,657 shares were sold at a weighted average price of $80.7326 per share, with actual prices ranging from $80.15 to $81.12.
  • Second sale tranche: 1,676 shares were sold at a weighted average price of $81.5226 per share, with actual prices ranging from $81.17 to $82.07.
  • Remaining direct ownership: Following all transactions, Vieira directly held 3,946 shares of common stock.
  • Remaining options: 125,001 stock options (right to buy) remain beneficially owned following the reported exercise.
  • 10b5-1 plan: The sales were made pursuant to a 10b5-1 plan adopted by Vieira on June 17, 2026, prior to his appointment as an officer of the issuer.

Vieira's November 2026 Option Exercise and Share Sales at Corcept Therapeutics

According to the filing, Roberto Wandenkolk Vieira, serving as President, Oncology at Corcept Therapeutics Inc, exercised a stock option for 8,333 shares of common stock on November 2, 2026, at an exercise price of $21.63. The stock option, with an expiration date of February 1, 2034, had vesting terms under which 25% of the underlying shares became exercisable on January 29, 2025, with the remaining shares vesting ratably on a monthly basis over 36 consecutive months, until fully vested on January 29, 2028, subject to continued service.

On the same date, the filing discloses that Vieira sold shares in two separate tranches under a Rule 10b5-1 plan. The first tranche consisted of 6,657 shares at a weighted average price of $80.7326, with individual sale prices ranging from $80.15 to $81.12. The second tranche consisted of 1,676 shares at a weighted average price of $81.5226, with individual sale prices ranging from $81.17 to $82.07. The filing notes that the 10b5-1 plan was adopted on June 17, 2026, prior to Vieira being appointed an officer of the issuer.

After all reported transactions, Vieira directly held 3,946 shares of common stock. The filing notes that this total includes unvested restricted stock awards granted on December 1, 2025 (179 shares), March 2, 2026 (396 shares), June 1, 2026 (634 shares), and September 1, 2026 (138 shares), with each award vesting 100% on its one-year anniversary, subject to certain requirements. Vieira also retained 125,001 stock options following the exercise.

What Was Disclosed

The filing reports a stock option exercise of 8,333 shares and two subsequent share sales totaling 8,333 shares by Corcept Therapeutics' President of Oncology on November 2, 2026, all executed under a pre-established 10b5-1 plan.